losartan has been researched along with Tachycardia, Ventricular in 6 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Tachycardia, Ventricular: An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rats harboring the human renin and angiotensinogen genes (dTGR) feature angiotensin (ANG) II/hypertension-induced cardiac damage and die suddenly between wk 7 and 8." | 3.74 | Angiotensin II-induced sudden arrhythmic death and electrical remodeling. ( Dechend, R; Dietz, R; Fiebeler, A; Fischer, R; Gapelyuk, A; Gratze, P; Gruner, A; Gruner, K; Luft, FC; Muller, DN; Qadri, F; Schirdewan, A; Shagdarsuren, E; Wellner, M, 2007) |
| "Ischemic focal ventricular tachycardia (VT) occurs in animals and humans." | 1.35 | Angiotensin II effects on ischemic focal ventricular tachycardia are predominantly mediated through myocardial AT(2) receptor. ( Chaudhary, AK; Ely, D; Gopinathannair, R; Martins, JB; Xing, D; Zheng, W, 2009) |
| " In dose-finding experiments in non-hypertrophied isolated perfused hearts, we performed dose-response curves of losartan and enalaprilat studying monophasic action potential duration at 90% repolarisation (MAPD(90%)) and ventricular fibrillation (VF) threshold." | 1.32 | Losartan but not enalaprilat acutely reduces reperfusion ventricular tachyarrhythmias in hypertrophied rat hearts after low-flow ischaemia. ( Beier, K; Bellahcene, M; Buser, PT; Butz, S; Driamov, S; Remondino, A; Zaugg, CE; Ziegler, A, 2004) |
| "The incidence of ventricular tachyarrhythmias during reperfusion was lower in the losartan group than in the control group (4/15 vs 6/15)." | 1.30 | Effects of an angiotensin II antagonist on reperfusion arrhythmias in dogs. ( Annoura, M; Arakawa, K; Handa, K; Hiroki, T; Kumagai, K; Matsuo, K; Nakashima, Y; Yamanouchi, Y, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gopinathannair, R | 1 |
| Chaudhary, AK | 1 |
| Xing, D | 1 |
| Ely, D | 1 |
| Zheng, W | 1 |
| Martins, JB | 1 |
| Butz, S | 1 |
| Driamov, S | 1 |
| Remondino, A | 1 |
| Bellahcene, M | 1 |
| Beier, K | 1 |
| Ziegler, A | 1 |
| Buser, PT | 1 |
| Zaugg, CE | 1 |
| Gao, L | 1 |
| Wang, W | 1 |
| Li, YL | 1 |
| Schultz, HD | 1 |
| Liu, D | 1 |
| Cornish, KG | 1 |
| Zucker, IH | 1 |
| Pourdjabbar, A | 1 |
| Parker, TG | 1 |
| Nguyen, QT | 1 |
| Desjardins, JF | 1 |
| Lapointe, N | 1 |
| Tsoporis, JN | 1 |
| Rouleau, JL | 1 |
| Fischer, R | 1 |
| Dechend, R | 1 |
| Gapelyuk, A | 1 |
| Shagdarsuren, E | 1 |
| Gruner, K | 1 |
| Gruner, A | 1 |
| Gratze, P | 1 |
| Qadri, F | 1 |
| Wellner, M | 1 |
| Fiebeler, A | 1 |
| Dietz, R | 1 |
| Luft, FC | 1 |
| Muller, DN | 1 |
| Schirdewan, A | 1 |
| Matsuo, K | 1 |
| Kumagai, K | 1 |
| Annoura, M | 1 |
| Yamanouchi, Y | 1 |
| Handa, K | 1 |
| Nakashima, Y | 1 |
| Hiroki, T | 1 |
| Arakawa, K | 1 |
6 other studies available for losartan and Tachycardia, Ventricular
| Article | Year |
|---|---|
Angiotensin II effects on ischemic focal ventricular tachycardia are predominantly mediated through myocardial AT(2) receptor.
Topics: Action Potentials; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Re | 2009 |
Losartan but not enalaprilat acutely reduces reperfusion ventricular tachyarrhythmias in hypertrophied rat hearts after low-flow ischaemia.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Enalaprilat; H | 2004 |
Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Ditiocarb; Heart F | 2004 |
Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Blood Pressure; | 2005 |
Angiotensin II-induced sudden arrhythmic death and electrical remodeling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Animals, Genetica | 2007 |
Effects of an angiotensin II antagonist on reperfusion arrhythmias in dogs.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac | 1997 |